BioStock: Aptahem's chief operating officer on the plans for 2021

The most anticipated milestone for sepsis company Aptahem is initiating first-in-human trials with candidate Apta-1, which is planned for next year. BioStock got in touch with the company’s chief operating officer Ulf Björklund, to learn more about the work on the GLP toxicology studies. We also get his view on what the visions are for the company and what potential he sees in Apta-1.

Read the full interview with Ulf Björklund at biostock.se:

https://www.biostock.se/en/aptahems-chief-operating-officer-on-the-plans-for-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se